|
David Zopf joined Immune Control Inc. in January 2008. His previous experience includes 15 years in various executive roles at Neose Technologies, Inc., where he was most recently Executive Vice President and Chief Scientific Officer. At Neose he managed discovery and development of new products and technologies and was co-inventor on many patents pertaining to oligosaccharide anti-infectives and the use of GlycoPEGylationtm technology to develop and manufacture second generation glycoprotein drugs. David contributed to IND filings that led to five clinical trials, including ongoing trials of long-acting forms of G-CSF and Factor VIIa. After receiving his AB and M.D. degrees from Washington University in St. Louis, David pursued an academic career for 17 years at the National Cancer Institute where he served as Chief of the Section on Biochemical Pathology. During that time he authored more than 70 peer reviewed publications focused on structure/function relationships of biologically active complex carbohydrates. | 